Insider Transactions in Q2 2023 at Arrowhead Pharmaceuticals, Inc. (ARWR)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2023
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
3,000
-1.57%
|
$105,000
$35.53 P/Share
|
|
Jun 27
2023
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-3.78%
|
$540,000
$36.2 P/Share
|
|
May 05
2023
|
Douglas B Given Director |
SELL
Open market or private sale
|
Direct |
6,500
-5.24%
|
$260,000
$40.9 P/Share
|
|
May 04
2023
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
50,000
-0.66%
|
$1,950,000
$39.5 P/Share
|
|
May 04
2023
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+1.29%
|
$100,000
$2.01 P/Share
|
|
May 03
2023
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
54,928
-1.44%
|
$2,142,192
$39.14 P/Share
|
|
May 03
2023
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
54,928
+1.42%
|
$109,856
$2.01 P/Share
|